Mersana Therapeutics Inc at JPMorgan Healthcare Conference Transcript
Hi. I'm Yuko Oku, one of the associates on the biotech team. It's a pleasure to introduce Mersana to the JPMorgan Healthcare Conference today. Just a quick housekeeping note, we'll be hosting a Q&A session right after the presentation in the Victorian Room. And with that, I'd like to turn it over to President and CEO, Anna Protopapas.
Thank you. Before I start, I just want to remind you that I will be making forward-looking statements. 2020 is a very important year for Mersana. It's a year rich in both milestones and data disclosures. Our lead asset, 1536, is a first-in-class molecule addressing important unmet medical needs in ovarian and lung adenocarcinoma. 1536 is in 2 proof-of-concept studies that are on track to complete in 2020 and then subsequently support registration-enabling studies, including fast-to-market opportunities in later-stage ovarian cancer patients.
Beyond 1536, we have a new IND and 2
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |